2m 2m 2m 2m 2m 2m 2m
- N/AMarket Cap
- -72.04%1-Year Change
- BiotechnologyIndustry
JYON (MENS)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400%
The U.S. IPO market is experiencing a strong revival in 2025, with 163 companies going public and raising $31 billion, driven by a favorable business climate under President Trump's second term and increased investor risk appetite.
10/07/2025, 4:09 PM • Benzinga
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.
09/03/2025, 7:30 AM • The Motley Fool
Jyong Biotech presented Phase III clinical trial results for BOTRESO, a drug for benign prostatic hyperplasia, and Phase II results for MCS-8, a potential prostate cancer prevention drug, at the 22nd Urological Association of Asia Congress.
08/22/2025, 9:00 AM • GlobeNewswire
Peers
- CNTACENTESSA SP ADS
$40.68+0.45%Market CapN/A1-Year Change+185.21%
Statistics
MoreInformation as of 07/02/2026
Company Profile
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Key Executives
- Wei Zhang
- Wanwen Su
- Fu-Feng Kuo
- Fenglin Hsu
Current Ownership Distribution
- Other75.6M (99.39%)
- Institutions453,640 (0.60%)
- Mutual Funds8,476 (0.01%)
- Insiders0 (0.00%)